Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和ZW251（GPC3靶向ADC），后者在肝细胞癌模型中表现出色，预计2025年 ...

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Zymeworks (ZYME – Research Report), with a price target ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session.

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...

Shares of ZYME stock opened at $11.70 on Tuesday. The company has a market capitalization of $814.05 million, a PE ratio of -7.80 and a beta of 1.13. The firm’s 50-day moving average is $14.01 ...

The firm increased its portfolio allocation in ZYME by 44.10% over the last quarter. Redmile Group holds 4,840K shares representing 6.96% ownership of the company. In its prior filing, the firm ...